GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial

被引：0

作者：

Shen, Lin ^{[1
]}

Gong, Jifang ^{[1
]}

Song, Yuqin ^{[2
]}

Ye, Dingwei ^{[3
]}

Lu, Zhihao ^{[1
]}

Wang, Siyang ^{[4
]}

Peng, Peijian ^{[4
]}

Chen, Jianhua ^{[5
]}

Jiang, Ou ^{[6
]}

Zhang, Guojun ^{[7
]}

Bai, Yuxian ^{[8
]}

Pan, Jianji ^{[9
]}

Ma, Chunguang ^{[3
]}

Chen, Li ^{[10
]}

Ba, Yi ^{[11
]}

Li, Qi ^{[12
]}

Lu, Ping ^{[13
]}

Zhang, Lingli ^{[14
]}

Yin, Xianli ^{[15
]}

Gu, Shanzhi ^{[15
]}

Zhang, Huilai ^{[16
]}

Su, Hang ^{[17
]}

Jiang, Yongsheng ^{[18
,19
]}

Cao, Bangwei ^{[20
]}

Han, Weiqing ^{[15
]}

Sun, Yan ^{[21
]}

Zhang, Feng ^{[22
]}

Ouyang, Weiwei ^{[23
]}

Dong, Haiying ^{[24
]}

Guo, Jianming ^{[25
]}

Guo, Yabing ^{[26
]}

Xu, Chongyuan ^{[26
]}

Qi, Junyuan ^{[27
]}

Wang, Li ^{[28
]}

Lv, Jun ^{[29
]}

Wang, Xiang ^{[12
]}

Chen, Chris ^{[30
]}

Li, Jing ^{[30
]}

Zheng, Yong ^{[30
]}

Jin, Ge ^{[31
]}

Yang, Yining ^{[31
]}

Zhao, Guodong ^{[31
]}

Yang, Fan ^{[32
]}

Xu, Kehui ^{[32
]}

Liang, Xiangying ^{[32
]}

Pan, Zhaoyang ^{[32
]}

Meng, Haijin ^{[32
]}

机构：

[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[2] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[3] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Urol, Shanghai, Peoples R China

[4] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China

[5] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp,Thorac Med Dept 1, Changsha, Peoples R China

[6] Second Gen Hosp Neijiang City, Neijiang, Peoples R China

[7] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[8] Harbin Med Univ, Canc Hosp, Haerbin, Peoples R China

[9] Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[10] Nanchang Univ, Affiliated Hosp 5, Nanchang, Jiangxi, Peoples R China

[11] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[12] Shanghai Gen Hosp, Shanghai, Peoples R China

[13] Xinxiang Med Sch, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China

[14] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[15] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China

[16] Tianjin Med Univ Canc Inst & Hosp, Lymphoma Dept, Tianjin, Peoples R China

[17] Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China

[18] Huazhong Univ Sci & Technol, Tongji Hosp, Wuhan, Peoples R China

[19] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan, Peoples R China

[20] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[21] Peking Univ Canc Hosp & Inst, Dept Oncol Radiotherapy, Beijing, Peoples R China

[22] Bengbu Med Sch, Affiliated Hosp 1, Bengbu, Peoples R China

[23] Guizhou Canc Hosp, Guiyang, Peoples R China

[24] Zhengjiang Prov Peoples Hosp, Hangzhou Med Coll, Peoples Hosp, Hangzhou, Peoples R China

[25] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[26] Nanfang Hosp, Southern Med Sch, Affiliated Hosp 1, Guangzhou, Peoples R China

[27] Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[28] Jiangsu Prov Hosp, Nanjing, Peoples R China

[29] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[30] WuXi Biol Shanghai Co Ltd, Shanghai, Peoples R China

[31] GloriousMed Technol Co Ltd, Beijing, Peoples R China

[32] Guangzhou Gloria Biosci Co Ltd, Beijing, Peoples R China

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-3275

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3275

引用

页数：4

共 50 条

[31] RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.
Zhou, Li
Xu, Huayan
Yan, Xieqiao
Chi, Zhihong
Cui, Chuanliang
Si, Lu
Tang, Bixia
Mao, Lili
Lian, Bin
Wang, Xuan
Li, Siming
Bai, Xue
Guo, Jun
Sheng, Xinan
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[32] Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
Que, Yi
Wang, Juan
Sun, Feifei
Wang, Shan
Zhu, Jia
Huang, Junting
Zhao, Zhenzhen
Zhang, Li
Liu, Juan
Xu, Jiaqian
Zhen, Zijun
Sun, Xiaofei
Lu, Suying
Zhang, Yizhuo
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
[33] Impact of BMI on clinical outcome in advanced cancer patients treated with anti-PD-1 Immune checkpoint inhibitors: a preliminary analysis
Cortellini, Alessio
De Tursi, Michele
Tinari, Nicola
Grassadonia, Antonino
Parisi, Alessandro
Iezzi, Laura
Di Marino, Pietro
D'Ostilio, Nicola
Brocco, Davide
Bersanelli, Melissa
Peri, Marta
Cannita, Katia
Ficorella, Corrado
Natoli, Clara
JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17
[34] Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
Yi Que
Juan Wang
Feifei Sun
Shan Wang
Jia Zhu
Junting Huang
Zhenzhen Zhao
Li Zhang
Juan Liu
Jiaqian Xu
Zijun Zhen
Xiaofei Sun
Suying Lu
Yizhuo Zhang
Signal Transduction and Targeted Therapy, 8
[35] Re: A Phase Ib Trial of Personalized Neoantigen Therapy plus Anti-PD-1 in Patients with Advanced Melanoma, Non-Small Cell Lung Cancer, or Bladder Cancer
Chang, Sam S.
JOURNAL OF UROLOGY, 2022, 207 (02): : 466 - 467
[36] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
Ganju, Vinod
Cooper, Adam
Gao, Bo
Wilkinson, Kate
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[37] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
Amita Patnaik
Glen J. Weiss
Drew W. Rasco
Lisa Blaydorn
Amy Mirabella
Murali Beeram
Wei Guo
Sharon Lu
Hadi Danaee
Kristen McEachern
Ellie Im
Jasgit C. Sachdev
Cancer Chemotherapy and Pharmacology, 2022, 89 : 93 - 103
[38] A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Initial results in patients refractory to checkpoint blockade
Zager, J. S.
Sarnaik, A. S.
Pilon-Thomas, S.
Beatty, M.
Han, D.
Lu, G.
Agarwala, S. S.
Ross, M.
Shirai, K.
Essner, R.
Smithers, B.
Atkinson, V. Victoria
Wachter, E.
ANNALS OF ONCOLOGY, 2020, 31 : S755 - S756
[39] Avelumab (MSB0010718C; anti-PD-L1), in Japanese patients with advanced gastric cancer: results from phase Ib trial
Hironaka, Shuichi
Shitara, Kohei
Iwasa, Satoru
Nishina, Tomohiro
Muro, Kei
Esaki, Taito
Satoh, Taroh
Hara, Hiroki
Machida, Nozomu
von Heydebreck, Anja
Shimizu, Akiko
Doi, Toshihiko
ANNALS OF ONCOLOGY, 2016, 27
[40] A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Results in patients naive to immune checkpoint blockade
Agarwala, S. S.
Ross, M.
Zager, J. S.
Sarnaik, A. S.
Shirai, K.
Lu, G.
Essner, R.
Smithers, B.
Atkinson, V. Victoria
Wachter, E.
ANNALS OF ONCOLOGY, 2020, 31 : S756 - S756

← 1 2 3 4 5 →